Medicinal Cannabis: Limited Evidence for Mental Health Conditions and Increased Prescribing Concerns

Recent research and updated guidance are raising questions about the widespread employ of medicinal cannabis, particularly for mental health conditions like depression, anxiety, and PTSD. Even as access to medicinal cannabis has expanded in Australia, evidence supporting its effectiveness for these conditions remains limited, and concerns are growing regarding unsafe prescribing practices.

Growing Concerns Over Prescribing Practices

The Australian Medical Association (AMA) has welcomed updated guidance from the Australian Health Practitioner Regulation Agency (Ahpra) aimed at addressing unsafe prescribing of medicinal cannabis. This move comes in response to a surge in prescriptions and increasing reports of patient harm, including psychosis [1]. The proliferation of direct-to-consumer telehealth models, which often bypass traditional regulatory frameworks and lack adequate referral pathways, is a key driver of this trend.

Dr. Danielle McMullen, AMA President, highlighted that current regulatory schemes were designed for a different healthcare system, one built around in-person consultations and community pharmacy dispensing. The rise of telehealth has created models that pose risks to patients and the broader health system [1].

Limited Evidence for Mental Health Applications

A review of data indicates that cannabis shows little benefit for most mental disorders. Research published in The Conversation and Reuters supports this finding, suggesting that medicinal cannabis is not an effective treatment for depression, anxiety, or PTSD [3]. The Australian Journal of Pharmacy has likewise published research questioning the routine use of medicinal cannabis, suggesting it could be doing more harm than good.

The Therapeutic Goods Administration (TGA) released clinical guidance documents in 2017, providing an overview of the evidence available at that time. A review conducted in February 2020 by the National Drug and Alcohol Research Centre found that the clinical evidence supporting medicinal cannabis use had not significantly changed since then [3].

The Australian Medicinal Cannabis Landscape

The Australian Medicinal Cannabis Association (AMCA) has recently merged with the Medical Cannabis Industry Association (MCIA) to form the Medicinal Cannabis Council Australia (MCCA), aiming to create a unified voice for the industry [1]. The MCCA focuses on improving patient access and affordability, advocating for the Australian medicinal cannabis industry, and working to change driving and employment laws related to medicinal cannabis use.

Safe Prescribing Guidelines

The Medical Board of Australia emphasizes that safe prescribing of medicinal cannabis requires thorough patient assessment, a well-formulated management plan, coordinated care, and detailed medical record-keeping [4]. Medicinal cannabis should not be a first-line treatment and should be prescribed with the same caution as other drugs of dependence.

Key Takeaways

• Evidence supporting the use of medicinal cannabis for mental health conditions is limited.
• Unsafe prescribing practices, particularly through telehealth, are a growing concern.
• The Australian medical community is working to improve regulations and ensure patient safety.
• Medicinal cannabis should not be considered a first-line treatment option.